Generic Drugs Industry Research Report 2024
Summary
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
According to APO Research, The global Generic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Generic Drugs include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Generic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Drugs.
The Generic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Generic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Generic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
According to APO Research, The global Generic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Generic Drugs include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Generic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Drugs.
The Generic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Generic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Teva
- Novartis - Sandoz
- Mylan
- Sun Pharmaceutical
- Aspen
- Fresenius Kabi
- Pfizer (Hospira)
- Sanofi
- Aurobindo
- Lupin
- Dr. Reddy's
- Apotex
- Cipla
- ENDO (Par Pharmaceutical)
- Stada Arzneimittel
- Krka Group
- Nichi-Iko Pharmaceutical
- Valeant
- Zydus Cadila
- Hikma
- Pharmaniaga Berhad
- Hovid Berhad
- Duopharma Biotech
- Kotra Pharma
- HOE Pharmaceutical
- Y.S.P. Industries
- Prescription
- Non-Prescription Drugs
- Hospital
- Clinic
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Generic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Generic Drugs by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Prescription
2.2.3 Non-Prescription Drugs
2.3 Generic Drugs by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Hospital
2.3.3 Clinic
2.3.4 Others
2.4 Assumptions and Limitations
3 GENERIC DRUGS BREAKDOWN DATA BY TYPE
3.1 Global Generic Drugs Historic Market Size by Type (2019-2024)
3.2 Global Generic Drugs Forecasted Market Size by Type (2025-2030)
4 GENERIC DRUGS BREAKDOWN DATA BY APPLICATION
4.1 Global Generic Drugs Historic Market Size by Application (2019-2024)
4.2 Global Generic Drugs Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Generic Drugs Market Perspective (2019-2030)
5.2 Global Generic Drugs Growth Trends by Region
5.2.1 Global Generic Drugs Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Generic Drugs Historic Market Size by Region (2019-2024)
5.2.3 Generic Drugs Forecasted Market Size by Region (2025-2030)
5.3 Generic Drugs Market Dynamics
5.3.1 Generic Drugs Industry Trends
5.3.2 Generic Drugs Market Drivers
5.3.3 Generic Drugs Market Challenges
5.3.4 Generic Drugs Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Generic Drugs Players by Revenue
6.1.1 Global Top Generic Drugs Players by Revenue (2019-2024)
6.1.2 Global Generic Drugs Revenue Market Share by Players (2019-2024)
6.2 Global Generic Drugs Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Generic Drugs Head office and Area Served
6.4 Global Generic Drugs Players, Product Type & Application
6.5 Global Generic Drugs Players, Date of Enter into This Industry
6.6 Global Generic Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Generic Drugs Market Size (2019-2030)
7.2 North America Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Generic Drugs Market Size by Country (2019-2024)
7.4 North America Generic Drugs Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Generic Drugs Market Size (2019-2030)
8.2 Europe Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Generic Drugs Market Size by Country (2019-2024)
8.4 Europe Generic Drugs Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Generic Drugs Market Size (2019-2030)
9.2 Asia-Pacific Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Generic Drugs Market Size by Country (2019-2024)
9.4 Asia-Pacific Generic Drugs Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Generic Drugs Market Size (2019-2030)
10.2 Latin America Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Generic Drugs Market Size by Country (2019-2024)
10.4 Latin America Generic Drugs Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Generic Drugs Market Size (2019-2030)
11.2 Middle East & Africa Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Generic Drugs Market Size by Country (2019-2024)
11.4 Middle East & Africa Generic Drugs Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 Teva
12.1.1 Teva Company Information
12.1.2 Teva Business Overview
12.1.3 Teva Revenue in Generic Drugs Business (2019-2024)
12.1.4 Teva Generic Drugs Product Portfolio
12.1.5 Teva Recent Developments
12.2 Novartis - Sandoz
12.2.1 Novartis - Sandoz Company Information
12.2.2 Novartis - Sandoz Business Overview
12.2.3 Novartis - Sandoz Revenue in Generic Drugs Business (2019-2024)
12.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
12.2.5 Novartis - Sandoz Recent Developments
12.3 Mylan
12.3.1 Mylan Company Information
12.3.2 Mylan Business Overview
12.3.3 Mylan Revenue in Generic Drugs Business (2019-2024)
12.3.4 Mylan Generic Drugs Product Portfolio
12.3.5 Mylan Recent Developments
12.4 Sun Pharmaceutical
12.4.1 Sun Pharmaceutical Company Information
12.4.2 Sun Pharmaceutical Business Overview
12.4.3 Sun Pharmaceutical Revenue in Generic Drugs Business (2019-2024)
12.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
12.4.5 Sun Pharmaceutical Recent Developments
12.5 Aspen
12.5.1 Aspen Company Information
12.5.2 Aspen Business Overview
12.5.3 Aspen Revenue in Generic Drugs Business (2019-2024)
12.5.4 Aspen Generic Drugs Product Portfolio
12.5.5 Aspen Recent Developments
12.6 Fresenius Kabi
12.6.1 Fresenius Kabi Company Information
12.6.2 Fresenius Kabi Business Overview
12.6.3 Fresenius Kabi Revenue in Generic Drugs Business (2019-2024)
12.6.4 Fresenius Kabi Generic Drugs Product Portfolio
12.6.5 Fresenius Kabi Recent Developments
12.7 Pfizer (Hospira)
12.7.1 Pfizer (Hospira) Company Information
12.7.2 Pfizer (Hospira) Business Overview
12.7.3 Pfizer (Hospira) Revenue in Generic Drugs Business (2019-2024)
12.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
12.7.5 Pfizer (Hospira) Recent Developments
12.8 Sanofi
12.8.1 Sanofi Company Information
12.8.2 Sanofi Business Overview
12.8.3 Sanofi Revenue in Generic Drugs Business (2019-2024)
12.8.4 Sanofi Generic Drugs Product Portfolio
12.8.5 Sanofi Recent Developments
12.9 Aurobindo
12.9.1 Aurobindo Company Information
12.9.2 Aurobindo Business Overview
12.9.3 Aurobindo Revenue in Generic Drugs Business (2019-2024)
12.9.4 Aurobindo Generic Drugs Product Portfolio
12.9.5 Aurobindo Recent Developments
12.10 Lupin
12.10.1 Lupin Company Information
12.10.2 Lupin Business Overview
12.10.3 Lupin Revenue in Generic Drugs Business (2019-2024)
12.10.4 Lupin Generic Drugs Product Portfolio
12.10.5 Lupin Recent Developments
12.11 Dr. Reddy's
12.11.1 Dr. Reddy's Company Information
12.11.2 Dr. Reddy's Business Overview
12.11.3 Dr. Reddy's Revenue in Generic Drugs Business (2019-2024)
12.11.4 Dr. Reddy's Generic Drugs Product Portfolio
12.11.5 Dr. Reddy's Recent Developments
12.12 Apotex
12.12.1 Apotex Company Information
12.12.2 Apotex Business Overview
12.12.3 Apotex Revenue in Generic Drugs Business (2019-2024)
12.12.4 Apotex Generic Drugs Product Portfolio
12.12.5 Apotex Recent Developments
12.13 Cipla
12.13.1 Cipla Company Information
12.13.2 Cipla Business Overview
12.13.3 Cipla Revenue in Generic Drugs Business (2019-2024)
12.13.4 Cipla Generic Drugs Product Portfolio
12.13.5 Cipla Recent Developments
12.14 ENDO (Par Pharmaceutical)
12.14.1 ENDO (Par Pharmaceutical) Company Information
12.14.2 ENDO (Par Pharmaceutical) Business Overview
12.14.3 ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2019-2024)
12.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
12.14.5 ENDO (Par Pharmaceutical) Recent Developments
12.15 Stada Arzneimittel
12.15.1 Stada Arzneimittel Company Information
12.15.2 Stada Arzneimittel Business Overview
12.15.3 Stada Arzneimittel Revenue in Generic Drugs Business (2019-2024)
12.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
12.15.5 Stada Arzneimittel Recent Developments
12.16 Krka Group
12.16.1 Krka Group Company Information
12.16.2 Krka Group Business Overview
12.16.3 Krka Group Revenue in Generic Drugs Business (2019-2024)
12.16.4 Krka Group Generic Drugs Product Portfolio
12.16.5 Krka Group Recent Developments
12.17 Nichi-Iko Pharmaceutical
12.17.1 Nichi-Iko Pharmaceutical Company Information
12.17.2 Nichi-Iko Pharmaceutical Business Overview
12.17.3 Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2019-2024)
12.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
12.17.5 Nichi-Iko Pharmaceutical Recent Developments
12.18 Valeant
12.18.1 Valeant Company Information
12.18.2 Valeant Business Overview
12.18.3 Valeant Revenue in Generic Drugs Business (2019-2024)
12.18.4 Valeant Generic Drugs Product Portfolio
12.18.5 Valeant Recent Developments
12.19 Zydus Cadila
12.19.1 Zydus Cadila Company Information
12.19.2 Zydus Cadila Business Overview
12.19.3 Zydus Cadila Revenue in Generic Drugs Business (2019-2024)
12.19.4 Zydus Cadila Generic Drugs Product Portfolio
12.19.5 Zydus Cadila Recent Developments
12.20 Hikma
12.20.1 Hikma Company Information
12.20.2 Hikma Business Overview
12.20.3 Hikma Revenue in Generic Drugs Business (2019-2024)
12.20.4 Hikma Generic Drugs Product Portfolio
12.20.5 Hikma Recent Developments
12.21 Pharmaniaga Berhad
12.21.1 Pharmaniaga Berhad Company Information
12.21.2 Pharmaniaga Berhad Business Overview
12.21.3 Pharmaniaga Berhad Revenue in Generic Drugs Business (2019-2024)
12.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
12.21.5 Pharmaniaga Berhad Recent Developments
12.22 Hovid Berhad
12.22.1 Hovid Berhad Company Information
12.22.2 Hovid Berhad Business Overview
12.22.3 Hovid Berhad Revenue in Generic Drugs Business (2019-2024)
12.22.4 Hovid Berhad Generic Drugs Product Portfolio
12.22.5 Hovid Berhad Recent Developments
12.23 Duopharma Biotech
12.23.1 Duopharma Biotech Company Information
12.23.2 Duopharma Biotech Business Overview
12.23.3 Duopharma Biotech Revenue in Generic Drugs Business (2019-2024)
12.23.4 Duopharma Biotech Generic Drugs Product Portfolio
12.23.5 Duopharma Biotech Recent Developments
12.24 Kotra Pharma
12.24.1 Kotra Pharma Company Information
12.24.2 Kotra Pharma Business Overview
12.24.3 Kotra Pharma Revenue in Generic Drugs Business (2019-2024)
12.24.4 Kotra Pharma Generic Drugs Product Portfolio
12.24.5 Kotra Pharma Recent Developments
12.25 HOE Pharmaceutical
12.25.1 HOE Pharmaceutical Company Information
12.25.2 HOE Pharmaceutical Business Overview
12.25.3 HOE Pharmaceutical Revenue in Generic Drugs Business (2019-2024)
12.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio
12.25.5 HOE Pharmaceutical Recent Developments
12.26 Y.S.P. Industries
12.26.1 Y.S.P. Industries Company Information
12.26.2 Y.S.P. Industries Business Overview
12.26.3 Y.S.P. Industries Revenue in Generic Drugs Business (2019-2024)
12.26.4 Y.S.P. Industries Generic Drugs Product Portfolio
12.26.5 Y.S.P. Industries Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Generic Drugs by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Prescription
2.2.3 Non-Prescription Drugs
2.3 Generic Drugs by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Hospital
2.3.3 Clinic
2.3.4 Others
2.4 Assumptions and Limitations
3 GENERIC DRUGS BREAKDOWN DATA BY TYPE
3.1 Global Generic Drugs Historic Market Size by Type (2019-2024)
3.2 Global Generic Drugs Forecasted Market Size by Type (2025-2030)
4 GENERIC DRUGS BREAKDOWN DATA BY APPLICATION
4.1 Global Generic Drugs Historic Market Size by Application (2019-2024)
4.2 Global Generic Drugs Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Generic Drugs Market Perspective (2019-2030)
5.2 Global Generic Drugs Growth Trends by Region
5.2.1 Global Generic Drugs Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Generic Drugs Historic Market Size by Region (2019-2024)
5.2.3 Generic Drugs Forecasted Market Size by Region (2025-2030)
5.3 Generic Drugs Market Dynamics
5.3.1 Generic Drugs Industry Trends
5.3.2 Generic Drugs Market Drivers
5.3.3 Generic Drugs Market Challenges
5.3.4 Generic Drugs Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Generic Drugs Players by Revenue
6.1.1 Global Top Generic Drugs Players by Revenue (2019-2024)
6.1.2 Global Generic Drugs Revenue Market Share by Players (2019-2024)
6.2 Global Generic Drugs Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Generic Drugs Head office and Area Served
6.4 Global Generic Drugs Players, Product Type & Application
6.5 Global Generic Drugs Players, Date of Enter into This Industry
6.6 Global Generic Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Generic Drugs Market Size (2019-2030)
7.2 North America Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Generic Drugs Market Size by Country (2019-2024)
7.4 North America Generic Drugs Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Generic Drugs Market Size (2019-2030)
8.2 Europe Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Generic Drugs Market Size by Country (2019-2024)
8.4 Europe Generic Drugs Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Generic Drugs Market Size (2019-2030)
9.2 Asia-Pacific Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Generic Drugs Market Size by Country (2019-2024)
9.4 Asia-Pacific Generic Drugs Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Generic Drugs Market Size (2019-2030)
10.2 Latin America Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Generic Drugs Market Size by Country (2019-2024)
10.4 Latin America Generic Drugs Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Generic Drugs Market Size (2019-2030)
11.2 Middle East & Africa Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Generic Drugs Market Size by Country (2019-2024)
11.4 Middle East & Africa Generic Drugs Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 Teva
12.1.1 Teva Company Information
12.1.2 Teva Business Overview
12.1.3 Teva Revenue in Generic Drugs Business (2019-2024)
12.1.4 Teva Generic Drugs Product Portfolio
12.1.5 Teva Recent Developments
12.2 Novartis - Sandoz
12.2.1 Novartis - Sandoz Company Information
12.2.2 Novartis - Sandoz Business Overview
12.2.3 Novartis - Sandoz Revenue in Generic Drugs Business (2019-2024)
12.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
12.2.5 Novartis - Sandoz Recent Developments
12.3 Mylan
12.3.1 Mylan Company Information
12.3.2 Mylan Business Overview
12.3.3 Mylan Revenue in Generic Drugs Business (2019-2024)
12.3.4 Mylan Generic Drugs Product Portfolio
12.3.5 Mylan Recent Developments
12.4 Sun Pharmaceutical
12.4.1 Sun Pharmaceutical Company Information
12.4.2 Sun Pharmaceutical Business Overview
12.4.3 Sun Pharmaceutical Revenue in Generic Drugs Business (2019-2024)
12.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
12.4.5 Sun Pharmaceutical Recent Developments
12.5 Aspen
12.5.1 Aspen Company Information
12.5.2 Aspen Business Overview
12.5.3 Aspen Revenue in Generic Drugs Business (2019-2024)
12.5.4 Aspen Generic Drugs Product Portfolio
12.5.5 Aspen Recent Developments
12.6 Fresenius Kabi
12.6.1 Fresenius Kabi Company Information
12.6.2 Fresenius Kabi Business Overview
12.6.3 Fresenius Kabi Revenue in Generic Drugs Business (2019-2024)
12.6.4 Fresenius Kabi Generic Drugs Product Portfolio
12.6.5 Fresenius Kabi Recent Developments
12.7 Pfizer (Hospira)
12.7.1 Pfizer (Hospira) Company Information
12.7.2 Pfizer (Hospira) Business Overview
12.7.3 Pfizer (Hospira) Revenue in Generic Drugs Business (2019-2024)
12.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
12.7.5 Pfizer (Hospira) Recent Developments
12.8 Sanofi
12.8.1 Sanofi Company Information
12.8.2 Sanofi Business Overview
12.8.3 Sanofi Revenue in Generic Drugs Business (2019-2024)
12.8.4 Sanofi Generic Drugs Product Portfolio
12.8.5 Sanofi Recent Developments
12.9 Aurobindo
12.9.1 Aurobindo Company Information
12.9.2 Aurobindo Business Overview
12.9.3 Aurobindo Revenue in Generic Drugs Business (2019-2024)
12.9.4 Aurobindo Generic Drugs Product Portfolio
12.9.5 Aurobindo Recent Developments
12.10 Lupin
12.10.1 Lupin Company Information
12.10.2 Lupin Business Overview
12.10.3 Lupin Revenue in Generic Drugs Business (2019-2024)
12.10.4 Lupin Generic Drugs Product Portfolio
12.10.5 Lupin Recent Developments
12.11 Dr. Reddy's
12.11.1 Dr. Reddy's Company Information
12.11.2 Dr. Reddy's Business Overview
12.11.3 Dr. Reddy's Revenue in Generic Drugs Business (2019-2024)
12.11.4 Dr. Reddy's Generic Drugs Product Portfolio
12.11.5 Dr. Reddy's Recent Developments
12.12 Apotex
12.12.1 Apotex Company Information
12.12.2 Apotex Business Overview
12.12.3 Apotex Revenue in Generic Drugs Business (2019-2024)
12.12.4 Apotex Generic Drugs Product Portfolio
12.12.5 Apotex Recent Developments
12.13 Cipla
12.13.1 Cipla Company Information
12.13.2 Cipla Business Overview
12.13.3 Cipla Revenue in Generic Drugs Business (2019-2024)
12.13.4 Cipla Generic Drugs Product Portfolio
12.13.5 Cipla Recent Developments
12.14 ENDO (Par Pharmaceutical)
12.14.1 ENDO (Par Pharmaceutical) Company Information
12.14.2 ENDO (Par Pharmaceutical) Business Overview
12.14.3 ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2019-2024)
12.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
12.14.5 ENDO (Par Pharmaceutical) Recent Developments
12.15 Stada Arzneimittel
12.15.1 Stada Arzneimittel Company Information
12.15.2 Stada Arzneimittel Business Overview
12.15.3 Stada Arzneimittel Revenue in Generic Drugs Business (2019-2024)
12.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
12.15.5 Stada Arzneimittel Recent Developments
12.16 Krka Group
12.16.1 Krka Group Company Information
12.16.2 Krka Group Business Overview
12.16.3 Krka Group Revenue in Generic Drugs Business (2019-2024)
12.16.4 Krka Group Generic Drugs Product Portfolio
12.16.5 Krka Group Recent Developments
12.17 Nichi-Iko Pharmaceutical
12.17.1 Nichi-Iko Pharmaceutical Company Information
12.17.2 Nichi-Iko Pharmaceutical Business Overview
12.17.3 Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2019-2024)
12.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
12.17.5 Nichi-Iko Pharmaceutical Recent Developments
12.18 Valeant
12.18.1 Valeant Company Information
12.18.2 Valeant Business Overview
12.18.3 Valeant Revenue in Generic Drugs Business (2019-2024)
12.18.4 Valeant Generic Drugs Product Portfolio
12.18.5 Valeant Recent Developments
12.19 Zydus Cadila
12.19.1 Zydus Cadila Company Information
12.19.2 Zydus Cadila Business Overview
12.19.3 Zydus Cadila Revenue in Generic Drugs Business (2019-2024)
12.19.4 Zydus Cadila Generic Drugs Product Portfolio
12.19.5 Zydus Cadila Recent Developments
12.20 Hikma
12.20.1 Hikma Company Information
12.20.2 Hikma Business Overview
12.20.3 Hikma Revenue in Generic Drugs Business (2019-2024)
12.20.4 Hikma Generic Drugs Product Portfolio
12.20.5 Hikma Recent Developments
12.21 Pharmaniaga Berhad
12.21.1 Pharmaniaga Berhad Company Information
12.21.2 Pharmaniaga Berhad Business Overview
12.21.3 Pharmaniaga Berhad Revenue in Generic Drugs Business (2019-2024)
12.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
12.21.5 Pharmaniaga Berhad Recent Developments
12.22 Hovid Berhad
12.22.1 Hovid Berhad Company Information
12.22.2 Hovid Berhad Business Overview
12.22.3 Hovid Berhad Revenue in Generic Drugs Business (2019-2024)
12.22.4 Hovid Berhad Generic Drugs Product Portfolio
12.22.5 Hovid Berhad Recent Developments
12.23 Duopharma Biotech
12.23.1 Duopharma Biotech Company Information
12.23.2 Duopharma Biotech Business Overview
12.23.3 Duopharma Biotech Revenue in Generic Drugs Business (2019-2024)
12.23.4 Duopharma Biotech Generic Drugs Product Portfolio
12.23.5 Duopharma Biotech Recent Developments
12.24 Kotra Pharma
12.24.1 Kotra Pharma Company Information
12.24.2 Kotra Pharma Business Overview
12.24.3 Kotra Pharma Revenue in Generic Drugs Business (2019-2024)
12.24.4 Kotra Pharma Generic Drugs Product Portfolio
12.24.5 Kotra Pharma Recent Developments
12.25 HOE Pharmaceutical
12.25.1 HOE Pharmaceutical Company Information
12.25.2 HOE Pharmaceutical Business Overview
12.25.3 HOE Pharmaceutical Revenue in Generic Drugs Business (2019-2024)
12.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio
12.25.5 HOE Pharmaceutical Recent Developments
12.26 Y.S.P. Industries
12.26.1 Y.S.P. Industries Company Information
12.26.2 Y.S.P. Industries Business Overview
12.26.3 Y.S.P. Industries Revenue in Generic Drugs Business (2019-2024)
12.26.4 Y.S.P. Industries Generic Drugs Product Portfolio
12.26.5 Y.S.P. Industries Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
LIST OF TABLES
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Generic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Generic Drugs Revenue Market Share by Type (2018-2023)
Table 7. Global Generic Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Generic Drugs Revenue Market Share by Type (2024-2029)
Table 9. Global Generic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Generic Drugs Revenue Market Share by Application (2018-2023)
Table 11. Global Generic Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Generic Drugs Revenue Market Share by Application (2024-2029)
Table 13. Global Generic Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Generic Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Generic Drugs Market Share by Region (2018-2023)
Table 16. Global Generic Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Generic Drugs Market Share by Region (2024-2029)
Table 18. Generic Drugs Market Trends
Table 19. Generic Drugs Market Drivers
Table 20. Generic Drugs Market Challenges
Table 21. Generic Drugs Market Restraints
Table 22. Global Top Generic Drugs Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Generic Drugs Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Generic Drugs Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Generic Drugs, Headquarters and Area Served
Table 26. Global Generic Drugs Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Generic Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Generic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Generic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Generic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Generic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Generic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Generic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Generic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Generic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Generic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Generic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. Teva Company Detail
Table 46. Teva Business Overview
Table 47. Teva Generic Drugs Product
Table 48. Teva Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 49. Teva Recent Development
Table 50. Novartis - Sandoz Company Detail
Table 51. Novartis - Sandoz Business Overview
Table 52. Novartis - Sandoz Generic Drugs Product
Table 53. Novartis - Sandoz Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 54. Novartis - Sandoz Recent Development
Table 55. Mylan Company Detail
Table 56. Mylan Business Overview
Table 57. Mylan Generic Drugs Product
Table 58. Mylan Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 59. Mylan Recent Development
Table 60. Sun Pharmaceutical Company Detail
Table 61. Sun Pharmaceutical Business Overview
Table 62. Sun Pharmaceutical Generic Drugs Product
Table 63. Sun Pharmaceutical Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 64. Sun Pharmaceutical Recent Development
Table 65. Aspen Company Detail
Table 66. Aspen Business Overview
Table 67. Aspen Generic Drugs Product
Table 68. Aspen Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 69. Aspen Recent Development
Table 70. Fresenius Kabi Company Detail
Table 71. Fresenius Kabi Business Overview
Table 72. Fresenius Kabi Generic Drugs Product
Table 73. Fresenius Kabi Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 74. Fresenius Kabi Recent Development
Table 75. Pfizer (Hospira) Company Detail
Table 76. Pfizer (Hospira) Business Overview
Table 77. Pfizer (Hospira) Generic Drugs Product
Table 78. Pfizer (Hospira) Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 79. Pfizer (Hospira) Recent Development
Table 80. Sanofi Company Detail
Table 81. Sanofi Business Overview
Table 82. Sanofi Generic Drugs Product
Table 83. Sanofi Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 84. Sanofi Recent Development
Table 85. Aurobindo Company Detail
Table 86. Aurobindo Business Overview
Table 87. Aurobindo Generic Drugs Product
Table 88. Aurobindo Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 89. Aurobindo Recent Development
Table 90. Lupin Company Detail
Table 91. Lupin Business Overview
Table 92. Lupin Generic Drugs Product
Table 93. Lupin Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 94. Lupin Recent Development
Table 95. Dr. Reddy's Company Detail
Table 96. Dr. Reddy's Business Overview
Table 97. Dr. Reddy's Generic DrugsProduct
Table 98. Dr. Reddy's Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 99. Dr. Reddy's Recent Development
Table 100. Apotex Company Detail
Table 101. Apotex Business Overview
Table 102. Apotex Generic DrugsProduct
Table 103. Apotex Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 104. Apotex Recent Development
Table 105. Cipla Company Detail
Table 106. Cipla Business Overview
Table 107. Cipla Generic DrugsProduct
Table 108. Cipla Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 109. Cipla Recent Development
Table 110. ENDO (Par Pharmaceutical) Company Detail
Table 111. ENDO (Par Pharmaceutical) Business Overview
Table 112. ENDO (Par Pharmaceutical) Generic DrugsProduct
Table 113. ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 114. ENDO (Par Pharmaceutical) Recent Development
Table 115. Stada Arzneimittel Company Detail
Table 116. Stada Arzneimittel Business Overview
Table 117. Stada Arzneimittel Generic DrugsProduct
Table 118. Stada Arzneimittel Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 119. Stada Arzneimittel Recent Development
Table 120. Krka Group Company Detail
Table 121. Krka Group Business Overview
Table 122. Krka Group Generic DrugsProduct
Table 123. Krka Group Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 124. Krka Group Recent Development
Table 125. Nichi-Iko Pharmaceutical Company Detail
Table 126. Nichi-Iko Pharmaceutical Business Overview
Table 127. Nichi-Iko Pharmaceutical Generic DrugsProduct
Table 128. Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 129. Nichi-Iko Pharmaceutical Recent Development
Table 130. Valeant Company Detail
Table 131. Valeant Business Overview
Table 132. Valeant Generic DrugsProduct
Table 133. Valeant Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 134. Valeant Recent Development
Table 135. Zydus Cadila Company Detail
Table 136. Zydus Cadila Business Overview
Table 137. Zydus Cadila Generic DrugsProduct
Table 138. Zydus Cadila Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 139. Zydus Cadila Recent Development
Table 140. Hikma Company Detail
Table 141. Hikma Business Overview
Table 142. Hikma Generic DrugsProduct
Table 143. Hikma Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 144. Hikma Recent Development
Table 145. Pharmaniaga Berhad Company Detail
Table 146. Pharmaniaga Berhad Business Overview
Table 147. Pharmaniaga Berhad Generic DrugsProduct
Table 148. Pharmaniaga Berhad Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 149. Pharmaniaga Berhad Recent Development
Table 150. Hovid Berhad Company Detail
Table 151. Hovid Berhad Business Overview
Table 152. Hovid Berhad Generic DrugsProduct
Table 153. Hovid Berhad Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 154. Hovid Berhad Recent Development
Table 155. Duopharma Biotech Company Detail
Table 156. Duopharma Biotech Business Overview
Table 157. Duopharma Biotech Generic DrugsProduct
Table 158. Duopharma Biotech Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 159. Duopharma Biotech Recent Development
Table 160. Kotra Pharma Company Detail
Table 161. Kotra Pharma Business Overview
Table 162. Kotra Pharma Generic DrugsProduct
Table 163. Kotra Pharma Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 164. Kotra Pharma Recent Development
Table 165. HOE Pharmaceutical Company Detail
Table 166. HOE Pharmaceutical Business Overview
Table 167. HOE Pharmaceutical Generic DrugsProduct
Table 168. HOE Pharmaceutical Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 169. HOE Pharmaceutical Recent Development
Table 170. Y.S.P. Industries Company Detail
Table 171. Y.S.P. Industries Business Overview
Table 172. Y.S.P. Industries Generic DrugsProduct
Table 173. Y.S.P. Industries Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 174. Y.S.P. Industries Recent Development
Table 175. Teva Company Information
Table 176. Teva Business Overview
Table 177. Teva Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 178. Teva Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 179. Teva Recent Development
Table 180. Novartis - Sandoz Company Information
Table 181. Novartis - Sandoz Business Overview
Table 182. Novartis - Sandoz Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 183. Novartis - Sandoz Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 184. Novartis - Sandoz Recent Development
Table 185. Mylan Company Information
Table 186. Mylan Business Overview
Table 187. Mylan Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 188. Mylan Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 189. Mylan Recent Development
Table 190. Sun Pharmaceutical Company Information
Table 191. Sun Pharmaceutical Business Overview
Table 192. Sun Pharmaceutical Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 193. Sun Pharmaceutical Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 194. Sun Pharmaceutical Recent Development
Table 195. Aspen Company Information
Table 196. Aspen Business Overview
Table 197. Aspen Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 198. Aspen Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 199. Aspen Recent Development
Table 200. Fresenius Kabi Company Information
Table 201. Fresenius Kabi Business Overview
Table 202. Fresenius Kabi Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 203. Fresenius Kabi Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 204. Fresenius Kabi Recent Development
Table 205. Pfizer (Hospira) Company Information
Table 206. Pfizer (Hospira) Business Overview
Table 207. Pfizer (Hospira) Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 208. Pfizer (Hospira) Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 209. Pfizer (Hospira) Recent Development
Table 210. Sanofi Company Information
Table 211. Sanofi Business Overview
Table 212. Sanofi Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 213. Sanofi Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 214. Sanofi Recent Development
Table 215. Aurobindo Company Information
Table 216. Aurobindo Business Overview
Table 217. Aurobindo Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 218. Aurobindo Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 219. Aurobindo Recent Development
Table 220. Lupin Company Information
Table 221. Lupin Business Overview
Table 222. Lupin Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 223. Lupin Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 224. Lupin Recent Development
Table 225. Dr. Reddy's Company Information
Table 226. Dr. Reddy's Business Overview
Table 227. Dr. Reddy's Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 228. Dr. Reddy's Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 229. Dr. Reddy's Recent Development
Table 230. Apotex Company Information
Table 231. Apotex Business Overview
Table 232. Apotex Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 233. Apotex Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 234. Apotex Recent Development
Table 235. Cipla Company Information
Table 236. Cipla Business Overview
Table 237. Cipla Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 238. Cipla Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 239. Cipla Recent Development
Table 240. ENDO (Par Pharmaceutical) Company Information
Table 241. ENDO (Par Pharmaceutical) Business Overview
Table 242. ENDO (Par Pharmaceutical) Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 243. ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 244. ENDO (Par Pharmaceutical) Recent Development
Table 245. Stada Arzneimittel Company Information
Table 246. Stada Arzneimittel Business Overview
Table 247. Stada Arzneimittel Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 248. Stada Arzneimittel Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 249. Stada Arzneimittel Recent Development
Table 250. Krka Group Company Information
Table 251. Krka Group Business Overview
Table 252. Krka Group Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 253. Krka Group Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 254. Krka Group Recent Development
Table 255. Nichi-Iko Pharmaceutical Company Information
Table 256. Nichi-Iko Pharmaceutical Business Overview
Table 257. Nichi-Iko Pharmaceutical Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 258. Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 259. Nichi-Iko Pharmaceutical Recent Development
Table 260. Valeant Company Information
Table 261. Valeant Business Overview
Table 262. Valeant Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 263. Valeant Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 264. Valeant Recent Development
Table 265. Zydus Cadila Company Information
Table 266. Zydus Cadila Business Overview
Table 267. Zydus Cadila Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 268. Zydus Cadila Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 269. Zydus Cadila Recent Development
Table 270. Hikma Company Information
Table 271. Hikma Business Overview
Table 272. Hikma Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 273. Hikma Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 274. Hikma Recent Development
Table 275. Pharmaniaga Berhad Company Information
Table 276. Pharmaniaga Berhad Business Overview
Table 277. Pharmaniaga Berhad Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 278. Pharmaniaga Berhad Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 279. Pharmaniaga Berhad Recent Development
Table 280. Hovid Berhad Company Information
Table 281. Hovid Berhad Business Overview
Table 282. Hovid Berhad Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 283. Hovid Berhad Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 284. Hovid Berhad Recent Development
Table 285. Duopharma Biotech Company Information
Table 286. Duopharma Biotech Business Overview
Table 287. Duopharma Biotech Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 288. Duopharma Biotech Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 289. Duopharma Biotech Recent Development
Table 290. Kotra Pharma Company Information
Table 291. Kotra Pharma Business Overview
Table 292. Kotra Pharma Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 293. Kotra Pharma Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 294. Kotra Pharma Recent Development
Table 295. HOE Pharmaceutical Company Information
Table 296. HOE Pharmaceutical Business Overview
Table 297. HOE Pharmaceutical Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 298. HOE Pharmaceutical Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 299. HOE Pharmaceutical Recent Development
Table 300. Y.S.P. Industries Company Information
Table 301. Y.S.P. Industries Business Overview
Table 302. Y.S.P. Industries Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 303. Y.S.P. Industries Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 304. Y.S.P. Industries Recent Development
Table 305. Authors List of This Report
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Generic Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Generic Drugs Revenue Market Share by Type (2018-2023)
Table 7. Global Generic Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Generic Drugs Revenue Market Share by Type (2024-2029)
Table 9. Global Generic Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Generic Drugs Revenue Market Share by Application (2018-2023)
Table 11. Global Generic Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Generic Drugs Revenue Market Share by Application (2024-2029)
Table 13. Global Generic Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Generic Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Generic Drugs Market Share by Region (2018-2023)
Table 16. Global Generic Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Generic Drugs Market Share by Region (2024-2029)
Table 18. Generic Drugs Market Trends
Table 19. Generic Drugs Market Drivers
Table 20. Generic Drugs Market Challenges
Table 21. Generic Drugs Market Restraints
Table 22. Global Top Generic Drugs Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Generic Drugs Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Generic Drugs Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Generic Drugs, Headquarters and Area Served
Table 26. Global Generic Drugs Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Generic Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Generic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Generic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Generic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Generic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Generic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Generic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Generic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Generic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Generic Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Generic Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. Teva Company Detail
Table 46. Teva Business Overview
Table 47. Teva Generic Drugs Product
Table 48. Teva Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 49. Teva Recent Development
Table 50. Novartis - Sandoz Company Detail
Table 51. Novartis - Sandoz Business Overview
Table 52. Novartis - Sandoz Generic Drugs Product
Table 53. Novartis - Sandoz Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 54. Novartis - Sandoz Recent Development
Table 55. Mylan Company Detail
Table 56. Mylan Business Overview
Table 57. Mylan Generic Drugs Product
Table 58. Mylan Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 59. Mylan Recent Development
Table 60. Sun Pharmaceutical Company Detail
Table 61. Sun Pharmaceutical Business Overview
Table 62. Sun Pharmaceutical Generic Drugs Product
Table 63. Sun Pharmaceutical Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 64. Sun Pharmaceutical Recent Development
Table 65. Aspen Company Detail
Table 66. Aspen Business Overview
Table 67. Aspen Generic Drugs Product
Table 68. Aspen Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 69. Aspen Recent Development
Table 70. Fresenius Kabi Company Detail
Table 71. Fresenius Kabi Business Overview
Table 72. Fresenius Kabi Generic Drugs Product
Table 73. Fresenius Kabi Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 74. Fresenius Kabi Recent Development
Table 75. Pfizer (Hospira) Company Detail
Table 76. Pfizer (Hospira) Business Overview
Table 77. Pfizer (Hospira) Generic Drugs Product
Table 78. Pfizer (Hospira) Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 79. Pfizer (Hospira) Recent Development
Table 80. Sanofi Company Detail
Table 81. Sanofi Business Overview
Table 82. Sanofi Generic Drugs Product
Table 83. Sanofi Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 84. Sanofi Recent Development
Table 85. Aurobindo Company Detail
Table 86. Aurobindo Business Overview
Table 87. Aurobindo Generic Drugs Product
Table 88. Aurobindo Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 89. Aurobindo Recent Development
Table 90. Lupin Company Detail
Table 91. Lupin Business Overview
Table 92. Lupin Generic Drugs Product
Table 93. Lupin Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 94. Lupin Recent Development
Table 95. Dr. Reddy's Company Detail
Table 96. Dr. Reddy's Business Overview
Table 97. Dr. Reddy's Generic DrugsProduct
Table 98. Dr. Reddy's Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 99. Dr. Reddy's Recent Development
Table 100. Apotex Company Detail
Table 101. Apotex Business Overview
Table 102. Apotex Generic DrugsProduct
Table 103. Apotex Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 104. Apotex Recent Development
Table 105. Cipla Company Detail
Table 106. Cipla Business Overview
Table 107. Cipla Generic DrugsProduct
Table 108. Cipla Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 109. Cipla Recent Development
Table 110. ENDO (Par Pharmaceutical) Company Detail
Table 111. ENDO (Par Pharmaceutical) Business Overview
Table 112. ENDO (Par Pharmaceutical) Generic DrugsProduct
Table 113. ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 114. ENDO (Par Pharmaceutical) Recent Development
Table 115. Stada Arzneimittel Company Detail
Table 116. Stada Arzneimittel Business Overview
Table 117. Stada Arzneimittel Generic DrugsProduct
Table 118. Stada Arzneimittel Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 119. Stada Arzneimittel Recent Development
Table 120. Krka Group Company Detail
Table 121. Krka Group Business Overview
Table 122. Krka Group Generic DrugsProduct
Table 123. Krka Group Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 124. Krka Group Recent Development
Table 125. Nichi-Iko Pharmaceutical Company Detail
Table 126. Nichi-Iko Pharmaceutical Business Overview
Table 127. Nichi-Iko Pharmaceutical Generic DrugsProduct
Table 128. Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 129. Nichi-Iko Pharmaceutical Recent Development
Table 130. Valeant Company Detail
Table 131. Valeant Business Overview
Table 132. Valeant Generic DrugsProduct
Table 133. Valeant Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 134. Valeant Recent Development
Table 135. Zydus Cadila Company Detail
Table 136. Zydus Cadila Business Overview
Table 137. Zydus Cadila Generic DrugsProduct
Table 138. Zydus Cadila Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 139. Zydus Cadila Recent Development
Table 140. Hikma Company Detail
Table 141. Hikma Business Overview
Table 142. Hikma Generic DrugsProduct
Table 143. Hikma Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 144. Hikma Recent Development
Table 145. Pharmaniaga Berhad Company Detail
Table 146. Pharmaniaga Berhad Business Overview
Table 147. Pharmaniaga Berhad Generic DrugsProduct
Table 148. Pharmaniaga Berhad Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 149. Pharmaniaga Berhad Recent Development
Table 150. Hovid Berhad Company Detail
Table 151. Hovid Berhad Business Overview
Table 152. Hovid Berhad Generic DrugsProduct
Table 153. Hovid Berhad Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 154. Hovid Berhad Recent Development
Table 155. Duopharma Biotech Company Detail
Table 156. Duopharma Biotech Business Overview
Table 157. Duopharma Biotech Generic DrugsProduct
Table 158. Duopharma Biotech Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 159. Duopharma Biotech Recent Development
Table 160. Kotra Pharma Company Detail
Table 161. Kotra Pharma Business Overview
Table 162. Kotra Pharma Generic DrugsProduct
Table 163. Kotra Pharma Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 164. Kotra Pharma Recent Development
Table 165. HOE Pharmaceutical Company Detail
Table 166. HOE Pharmaceutical Business Overview
Table 167. HOE Pharmaceutical Generic DrugsProduct
Table 168. HOE Pharmaceutical Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 169. HOE Pharmaceutical Recent Development
Table 170. Y.S.P. Industries Company Detail
Table 171. Y.S.P. Industries Business Overview
Table 172. Y.S.P. Industries Generic DrugsProduct
Table 173. Y.S.P. Industries Revenue in Generic Drugs Business (2017-2022) & (US$ Million)
Table 174. Y.S.P. Industries Recent Development
Table 175. Teva Company Information
Table 176. Teva Business Overview
Table 177. Teva Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 178. Teva Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 179. Teva Recent Development
Table 180. Novartis - Sandoz Company Information
Table 181. Novartis - Sandoz Business Overview
Table 182. Novartis - Sandoz Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 183. Novartis - Sandoz Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 184. Novartis - Sandoz Recent Development
Table 185. Mylan Company Information
Table 186. Mylan Business Overview
Table 187. Mylan Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 188. Mylan Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 189. Mylan Recent Development
Table 190. Sun Pharmaceutical Company Information
Table 191. Sun Pharmaceutical Business Overview
Table 192. Sun Pharmaceutical Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 193. Sun Pharmaceutical Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 194. Sun Pharmaceutical Recent Development
Table 195. Aspen Company Information
Table 196. Aspen Business Overview
Table 197. Aspen Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 198. Aspen Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 199. Aspen Recent Development
Table 200. Fresenius Kabi Company Information
Table 201. Fresenius Kabi Business Overview
Table 202. Fresenius Kabi Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 203. Fresenius Kabi Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 204. Fresenius Kabi Recent Development
Table 205. Pfizer (Hospira) Company Information
Table 206. Pfizer (Hospira) Business Overview
Table 207. Pfizer (Hospira) Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 208. Pfizer (Hospira) Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 209. Pfizer (Hospira) Recent Development
Table 210. Sanofi Company Information
Table 211. Sanofi Business Overview
Table 212. Sanofi Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 213. Sanofi Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 214. Sanofi Recent Development
Table 215. Aurobindo Company Information
Table 216. Aurobindo Business Overview
Table 217. Aurobindo Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 218. Aurobindo Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 219. Aurobindo Recent Development
Table 220. Lupin Company Information
Table 221. Lupin Business Overview
Table 222. Lupin Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 223. Lupin Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 224. Lupin Recent Development
Table 225. Dr. Reddy's Company Information
Table 226. Dr. Reddy's Business Overview
Table 227. Dr. Reddy's Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 228. Dr. Reddy's Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 229. Dr. Reddy's Recent Development
Table 230. Apotex Company Information
Table 231. Apotex Business Overview
Table 232. Apotex Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 233. Apotex Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 234. Apotex Recent Development
Table 235. Cipla Company Information
Table 236. Cipla Business Overview
Table 237. Cipla Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 238. Cipla Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 239. Cipla Recent Development
Table 240. ENDO (Par Pharmaceutical) Company Information
Table 241. ENDO (Par Pharmaceutical) Business Overview
Table 242. ENDO (Par Pharmaceutical) Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 243. ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 244. ENDO (Par Pharmaceutical) Recent Development
Table 245. Stada Arzneimittel Company Information
Table 246. Stada Arzneimittel Business Overview
Table 247. Stada Arzneimittel Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 248. Stada Arzneimittel Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 249. Stada Arzneimittel Recent Development
Table 250. Krka Group Company Information
Table 251. Krka Group Business Overview
Table 252. Krka Group Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 253. Krka Group Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 254. Krka Group Recent Development
Table 255. Nichi-Iko Pharmaceutical Company Information
Table 256. Nichi-Iko Pharmaceutical Business Overview
Table 257. Nichi-Iko Pharmaceutical Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 258. Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 259. Nichi-Iko Pharmaceutical Recent Development
Table 260. Valeant Company Information
Table 261. Valeant Business Overview
Table 262. Valeant Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 263. Valeant Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 264. Valeant Recent Development
Table 265. Zydus Cadila Company Information
Table 266. Zydus Cadila Business Overview
Table 267. Zydus Cadila Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 268. Zydus Cadila Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 269. Zydus Cadila Recent Development
Table 270. Hikma Company Information
Table 271. Hikma Business Overview
Table 272. Hikma Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 273. Hikma Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 274. Hikma Recent Development
Table 275. Pharmaniaga Berhad Company Information
Table 276. Pharmaniaga Berhad Business Overview
Table 277. Pharmaniaga Berhad Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 278. Pharmaniaga Berhad Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 279. Pharmaniaga Berhad Recent Development
Table 280. Hovid Berhad Company Information
Table 281. Hovid Berhad Business Overview
Table 282. Hovid Berhad Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 283. Hovid Berhad Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 284. Hovid Berhad Recent Development
Table 285. Duopharma Biotech Company Information
Table 286. Duopharma Biotech Business Overview
Table 287. Duopharma Biotech Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 288. Duopharma Biotech Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 289. Duopharma Biotech Recent Development
Table 290. Kotra Pharma Company Information
Table 291. Kotra Pharma Business Overview
Table 292. Kotra Pharma Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 293. Kotra Pharma Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 294. Kotra Pharma Recent Development
Table 295. HOE Pharmaceutical Company Information
Table 296. HOE Pharmaceutical Business Overview
Table 297. HOE Pharmaceutical Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 298. HOE Pharmaceutical Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 299. HOE Pharmaceutical Recent Development
Table 300. Y.S.P. Industries Company Information
Table 301. Y.S.P. Industries Business Overview
Table 302. Y.S.P. Industries Generic DrugsRevenue in Generic Drugs Business (2018-2023) & (US$ Million)
Table 303. Y.S.P. Industries Revenue in Generic Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 304. Y.S.P. Industries Recent Development
Table 305. Authors List of This Report
LIST OF FIGURES
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Generic Drugs Product Picture
Figure 5. Global Generic Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Generic Drugs Market Share by Type: 2022 VS 2029
Figure 7. Prescription Product Picture
Figure 8. Non-Prescription Drugs Product Picture
Figure 9. Global Generic Drugs Market Size by Application (2023-2029) & (US$ Million)
Figure 10. Global Generic Drugs Market Share by Application: 2022 VS 2029
Figure 11. Hospital Product Picture
Figure 12. Clinic Product Picture
Figure 13. Others Product Picture
Figure 14. Global Generic Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Generic Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Generic Drugs Market Share by Region: 2022 VS 2029
Figure 17. Global Generic Drugs Market Share by Players in 2022
Figure 18.
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Generic Drugs Product Picture
Figure 5. Global Generic Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Generic Drugs Market Share by Type: 2022 VS 2029
Figure 7. Prescription Product Picture
Figure 8. Non-Prescription Drugs Product Picture
Figure 9. Global Generic Drugs Market Size by Application (2023-2029) & (US$ Million)
Figure 10. Global Generic Drugs Market Share by Application: 2022 VS 2029
Figure 11. Hospital Product Picture
Figure 12. Clinic Product Picture
Figure 13. Others Product Picture
Figure 14. Global Generic Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Generic Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Generic Drugs Market Share by Region: 2022 VS 2029
Figure 17. Global Generic Drugs Market Share by Players in 2022
Figure 18.
